Gelesis, a clinical stage company developing a new category of therapy
to safely treat overweight, obese and diabetic patients, has raised $12
million as it advances the development of its lead product, Gelesis100,
toward commercialization, bringing the total amount Gelesis has raised
to over $42 million.
GELESIS100 is a smart pill that is designed to treat the physiological symptoms of hunger without surgery, invasive procedures or systemic absorption. To date, Gelesis100 has generated compelling safety and efficacy data through a series of rigorous clinical, preclinical and in vitro studies.
GELESIS100 is a smart pill that is designed to treat the physiological symptoms of hunger without surgery, invasive procedures or systemic absorption. To date, Gelesis100 has generated compelling safety and efficacy data through a series of rigorous clinical, preclinical and in vitro studies.
No comments:
Post a Comment